Left Ventricular Hypertrophy Lvh
Mostrando 1-12 de 34 artigos, teses e dissertações.
-
1. Cardiac Manifestation of Fabry Disease: From Hypertrophic Cardiomyopathy to Early Diagnosis and Treatment in Patients Without Left Ventricular Hypertrophy
Abstract Although Fabry disease was identified a century ago, it is still a challenging condition to diagnose and treat. Registries data suggest that at least 10% of patients may first present with a cardiac event and that cardiac disease is 1 of the 3 major causes of morbidity and mortality in affected males and females. Cardiac involvement in Fabry disease
J. inborn errors metab. screen.. Publicado em: 30/05/2019
-
2. Echocardiographic Correlation between Right Ventricular Function and Left Atrial Volume
Resumo Fundamentos: A relação entre a disfunção diastólica do ventrículo esquerdo (DDVE), seus achados mais importantes, como aumento do átrio esquerdo e hipertrofia ventricular esquerda (HVE), e a função do ventrículo direito (VD) tem pouca documentação na literatura científica. Objetivo: Avaliar a correlação entre o tamanho atrial esquerdo
Arq. Bras. Cardiol.. Publicado em: 2019-03
-
3. MicroRNA profiling identifies miR-7-5p and miR-26b-5p as differentially expressed in hypertensive patients with left ventricular hypertrophy
Recent evidence suggests that cell-derived circulating miRNAs may serve as biomarkers of cardiovascular diseases. However, a few studies have investigated the potential of circulating miRNAs as biomarkers for left ventricular hypertrophy (LVH). In this study, we aimed to characterize the miRNA profiles that could distinguish hypertensive patients with LHV, h
Braz J Med Biol Res. Publicado em: 19/10/2017
-
4. ECG-based detection of left ventricle hypertrophy
Introduction Left ventricle hypertrophy (LVH) is an important risk factor for cardiovascular morbidity and mortality. It is characterized by a thickening of the walls of the left ventricle. The transthoracic echocardiogram is a very accurate method for LVH detection. However, the electrocardiogram (ECG) offers an alternative method in diagnosing LVH, besid
Res. Biomed. Eng.. Publicado em: 2015-04
-
5. Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment
Angiotensin-converting enzyme inhibitors reduce blood pressure and attenuate cardiac and vascular remodeling in hypertension. However, the kinetics of remodeling after discontinuation of the long-term use of these drugs are unknown. Our objective was to investigate the temporal changes occurring in blood pressure and vascular structure of spontaneously hyper
Brazilian Journal of Medical and Biological Research. Publicado em: 2010-04
-
6. Efeito protetivo da hipertrofia ventricular esquerda nas oclusoes de coronaria direita / Protective effect of left ventricular hypertrophy in right coronary artery occlusions
Objective - To test the hypothesis that left ventricular hypertrophy (LVH) reduces the electrocardiographic and functional effects of right coronary artery occlusion. Methods - We analysed 215 patients (166 males and 49 women,age of 58.9±10.6 years), with occlusion of the right coronary artery without other associated lesions. There was no significant diffe
Publicado em: 2010
-
7. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis
End-stage renal disease (ESRD) patients frequently develop structural cardiac abnormalities, particularly left ventricular hypertrophy (LVH). The mechanisms involved in these processes are not completely understood. In the present study, we evaluated a possible association between parathyroid hormone (PTH) levels and left ventricular mass (LVM) in patients w
Publicado em: 2010
-
8. Anti-hypertensive drugs have different effects on ventricular hypertrophy regression
OBJECTIVES: There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature. METHODS: The Medline (via PubMed), Lilacs and Scielo databases were searched us
Clinics. Publicado em: 2010
-
9. Estudo da morfologia e função cardíacas nos pacientes em hemodiálise com e sem diurese residual
Background: In patients with chronic renal disease (CRD) on hemodialysis (HD), left ventricular hypertrophy (LVH) is related to the increase in total peripheral vascular resistance (TPVR) and volume overload. The presence of residual diuresis (RD) enables greater control of these patients blood volume. Methodos: We evaluated the morpho-functional changes of
Publicado em: 2010
-
10. Hipertrofia ventricular esquerda em pacientes com doença renal crônica em hemodiálise: análise comparativa entre eletrocardiograma, radiografia de tórax e ecocardiograma. / Left ventricular hypertrophy in hemodialysis patients with chronic kidney disease: comparative analysis between electrocardiogram, chest radiography and echocardiogram.
Objective: To establish the diagnosis of left ventricular hypertrophy (LVH) in haemodialysis (HD) patients with chronic kidney disease (CKD) using seven different electrocardiographic criteria and chest radiography, and to correlate these two diagnostic methods with left ventricular mass index (LVMI) as obtained by echocardiogram. Methods: Cross-sectional st
Publicado em: 2009
-
11. RECLASSIFICAÇÃO DO RISCO CARDIOVASCULAR ESTIMADO PELO ESCORE DE FRAMINGHAM UTILIZANDO O CONCEITO DOS CRITÉRIOS AGRAVANTES / ESTIMATED RISK OF CARDIOVASCULAR REGRADING BY THE FRAMINGHAM SCORE USING THE CONCEPT OF CRITERIA AGGRAVATING
Coronary heart disease (CHD) is one of the main causes of death in the world and Framingham Risk Score (FRS) is the most used tool to assess the risk of CHD in asymptomatic patients. However, it underestimates the cardiovascular (CDV) risk in some individuals. To address this problem, Brazilian Society of Cardiology proposes further risk stratification tests
Publicado em: 2009
-
12. Anti-inflamatory effect of the S-nitroso-N-acetyleysteine (SNAC) on left ventricular hypertrophy in hypercholesterolemic LDLr/mice / Efeito antiinflamatorio da S-nitroso-N-acetilcisteina (SNAC) na hipertrofia ventricular esquerda (HVE) em camundongos hipercolesterolemicos knockout para o receptor de LDL (LDLr-/-)
Recently, it has been that S-nitroso-N-acetylcysteine (SNAC) attenuate in 55% the plaque development in low-density lipoprotein-receptor-deficient (LDLr-/-) mice fed a hypercholesterolemic diet for 15 days. The present study was designed to verify whether deletion of the low-density lipoprotein (LDL) receptor gene may affect the hemodynamic profile and adren
Publicado em: 2006